Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. - Wikidata - awgldk - TriplyDB

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

http://www.wikidata.org/entity/Q38673082

about

The safety of vedolizumab for the treatment of ulcerative colitis.Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Tumor necrosis factor suppresses interleukin 10 in peripheral B cells via upregulating Bcl2-like protein 12 in patients with inflammatory bowel disease.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Clinical performance of an infliximab rapid quantification assay.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels

P2860

Q30235363-051A46CB-F84C-450A-B4A7-A06835B246AE Q33584629-8E38F724-6222-4686-B95E-FF9981A921B2 Q37597661-61E0B3AD-AC38-4095-9650-7EA3B78C1662 Q38919270-B7D3A73B-659E-4FA1-8182-87949F7699ED Q39000759-A3A89CF4-46E2-46AB-A4F7-B79085116807 Q39030608-C3F7E1B9-10D7-44F4-B22A-F74A93759C96 Q41078459-91338CF4-8EEB-4ED6-A938-9ECD6785987F Q41078498-BDE86013-95C9-46CC-BC5C-17C080BBA9A3 Q47104100-884703A0-3F4C-442A-9F19-D072008651EF Q47805665-C2DAC8C5-A245-4EE4-9735-93AFE09B9630 Q49126220-872D36FD-48EA-4088-83A3-CBA95C29EFC1 Q58701964-07DA966A-D1BE-45C4-ACDB-6E4EBCA64242

P2860

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

http://www.wikidata.org/entity/Q38673082

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

@en

type

label

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

@en

prefLabel

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

@en

P1433

Q38673082-3C3A5589-DA11-421F-9139-BE6E8B49FC57

P1476

Q38673082-03037B4D-D5C1-4417-9744-1D5624C21D79

P2093

Q38673082-17E4683E-7F93-4401-A732-84938F965F1F

Q38673082-426CDB2E-D06F-4874-945B-139933BD0974

Q38673082-4DFF5AB5-0BC2-4511-A290-88C9175B1DAC

Q38673082-67C2F1BF-AC5C-4677-B554-41A984072106

P2860

Q38673082-017C2019-8591-4C8C-8758-BD8E16C94AB0

Q38673082-061906CF-828C-448B-85D4-D5710D1057CA

Q38673082-0BAF3057-132C-4A77-9039-D6BC7133A918

Q38673082-13935EE9-2CEB-4D5B-BE20-69D224C30F60

Q38673082-1DF36802-9E3F-4048-891F-E5F62B4218F3

Q38673082-25742982-5B33-41E5-8436-667C85502052

Q38673082-25D5732C-1CD0-4531-9D89-F3D57C52CA12

Q38673082-25D9E284-02F9-45AA-87DF-3B85574BE39F

Q38673082-27A3E815-D760-4A1C-9481-D54EE6F80F54

Q38673082-2CC548E3-84DA-46AB-89FA-E2DEB60C2923

P304

Q38673082-07AAAE0A-2F99-4683-B60E-9B0A0231B458

P31

Q38673082-7AFEE8D5-AFF1-41A7-9B68-E478EB2F1BFA

P356

Q38673082-6A1B3284-BB2E-43C7-9B13-9F849C9A3B99

P407

Q38673082-23E8E247-BC6C-4FA1-9513-F077DB0BCC55

P433

Q38673082-A034A810-5082-4C96-B2C6-AC540E0DE462

P478

Q38673082-10A95CF1-19C8-4B28-BE2E-A72BB365631A

P577

Q38673082-425C71B9-1568-4B58-8447-08179CC305E7

P698

Q38673082-F46127A7-77E9-49F0-BD6C-76419D40451A

P921

Q38673082-1804AAF8-5852-4468-A592-59B9BBB904E5

Q38673082-DED359AA-EA45-4868-BB6D-31690F07C1D7

P356

17512433.2016.1133288

P1433

Expert Review of Clinical Pharmacology

P1476

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.

@en

P2093

A S Strik

http://www.w3.org/2001/XMLSchema#string

G D'Haens

http://www.w3.org/2001/XMLSchema#string

M Löwenberg

http://www.w3.org/2001/XMLSchema#string

S J A Bots

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Disease monitoring in inflammatory bowel disease

Infliximab-Related Infusion Reactions: Systematic Review

Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

P304

429-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2016.1133288

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26681400

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases